Literature DB >> 35172359

Severe Infections Due to Respiratory Viruses.

Catia Cillóniz1, Juan M Pericàs2,3, Jorge R Rojas4, Antoni Torres1.   

Abstract

Severe viral infections may result in severe illnesses capable of causing acute respiratory failure that could progress rapidly to acute respiratory distress syndrome (ARDS), related to worse outcomes, especially in individuals with a higher risk of infection, including the elderly and those with comorbidities such as asthma, diabetes mellitus and chronic respiratory or cardiovascular disease. In addition, in cases of severe viral pneumonia, co-infection with bacteria such as Streptococcus pneumoniae and Staphylococcus aureus is related to worse outcomes. Respiratory viruses like influenza, rhinovirus, parainfluenza, adenovirus, metapneumovirus, respiratory syncytial virus, and coronavirus have increasingly been detected. This trend has become more prevalent, especially in critically ill patients, due to the availability and implementation of molecular assays in clinical practice. Respiratory viruses have been diagnosed as a frequent cause of severe pneumonia, including cases of community-acquired pneumonia, hospital-acquired pneumonia, and ventilator-associated pneumonia. In this review, we will discuss the epidemiology, diagnosis, clinical characteristics, management, and prognosis of patients with severe infections due to respiratory viruses, with a focus on influenza viruses, non-influenza viruses, and coronaviruses. Thieme. All rights reserved.

Entities:  

Mesh:

Year:  2022        PMID: 35172359     DOI: 10.1055/s-0041-1740982

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  1 in total

1.  Qiangli Wuhu mixture alleviates LPS-induced pneumonia by inhibiting the TLR4/NF-κB/NLRP3 pathway: a study based on network pharmacology.

Authors:  Jie Tian; Xiao-Long Wang; Long-Cheng Wang; Fei Chen; Yun Tian; Li Ma; Chao-Yun Pan; Yan-Ping Wang
Journal:  Pharm Biol       Date:  2022-12       Impact factor: 3.889

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.